Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Ionis Pharmaceuticals Inc Market Cap
From what 12 stock analysts predict, the share price for Ionis Pharmaceuticals Inc (IONS) might increase by 35.11% in the next year. This is based on a 12-month average estimation for IONS. Price targets go from $37.00 to $85.00. The majority of stock analysts believe IONS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
IONS is a stock in Health Care which has been forecasted to be worth $59.92 as an average. On the higher end, the forecast price is $85.00 USD by yanan zhu from Wells Fargo and on the lower end IONS is forecasted to be $37.00 by william pickering from Bernstein.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| jessica fye J.P. Morgan | Hold | $55.0 | maintained | Feb 1, 2024 |
| mani foroohar Leerink Partners | Hold | $48.0 | reiterated | Jan 22, 2024 |
| paul matteis Stifel Nicolaus | Hold | $50.0 | maintained | Dec 22, 2023 |
| gena wang Barclays | Hold | $45.0 | maintained | Nov 5, 2023 |
| michael ulz Morgan Stanley | Hold | $48.0 | maintained | Nov 3, 2023 |
| joseph schwartz SVB Securities | Hold | $34.0 | maintained | Feb 3, 2023 |
| matthew harrison Morgan Stanley | Hold | $30.0 | maintained | May 9, 2022 |
| aydin huseynov Ladenburg Thalmann & Co. | Hold | None | maintained | Oct 21, 2021 |
| tyler van buren TD Cowen | Hold | None | rated | Oct 1, 2021 |
| esther rajavelu UBS | Hold | $37.5 | upgraded | May 10, 2021 |
| eliana merle UBS | Hold | $59.0 | maintained | Sep 22, 2020 |
| ritu baral Cowen & Co. | Hold | None | maintained | Feb 27, 2020 |
| stephen willey Stifel Nicolaus | Hold | $48.0 | reiterated | Aug 6, 2018 |
| michael schmidt Guggenheim | Hold | $36.0 | reiterated | Oct 9, 2016 |
| jonathan eckard Barclays | Hold | $41.0 | reiterated | Aug 10, 2016 |
| navdeep singh Goldman Sachs | Hold | $65.0 | rated | Nov 18, 2015 |
| cory kasimov J.P. Morgan | Hold | $68.0 | maintained | Jun 8, 2015 |
| carol werther Dawson James | Hold | None | maintained | May 23, 2014 |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.
When did it IPO
0
Staff Count
796
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Brett P. Monia Ph.D.
Market Cap
$6.37B
In 2023, IONS generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IONS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
$84.09
EXEL-USD
$20.72
BBIO-USD
$33.6
FRSH-USD
$20.33
HLNE-USD
$117.61
$85.63
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
